Biotech Industry Examiner

Menu
Menu
subscribe now
Search
German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies

German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies

CatalYm, a German biotech company specializing in cancer immunotherapy, has

€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?

€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?

From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough

From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough

Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy

Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

MOST POPULAR

News

AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Light-Based Microcapillary Monitoring Expands Precision in Biotechnology
Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Funding

Aging Science

Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging

Genomics

M&A & Partnerships

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top